Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CEO Douglas S. Ingram acquired 38,138 shares of Sarepta Therapeutics stock in a transaction on Wednesday, November 8th. The stock was acquired at an average price of $52.44 per share, with a total value of $1,999,956.72. Following the purchase, the chief executive officer now directly owns 420,196 shares in the company, valued at $22,035,078.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Sarepta Therapeutics, Inc. (SRPT) opened at $54.49 on Tuesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. Sarepta Therapeutics, Inc. has a one year low of $26.26 and a one year high of $57.57.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.66. The business had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same period in the prior year, the company earned ($0.95) EPS. equities research analysts predict that Sarepta Therapeutics, Inc. will post -3.11 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Sarepta Therapeutics, Inc. (SRPT) CEO Douglas S. Ingram Acquires 38,138 Shares of Stock” was reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.truebluetribune.com/2017/11/14/sarepta-therapeutics-inc-srpt-ceo-douglas-s-ingram-acquires-38138-shares-of-stock.html.
A number of research analysts have issued reports on SRPT shares. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $71.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, October 6th. Credit Suisse Group set a $64.00 price objective on Sarepta Therapeutics and gave the company a “buy” rating in a research note on Tuesday, July 18th. Leerink Swann restated a “buy” rating and issued a $60.00 price objective (up previously from $52.00) on shares of Sarepta Therapeutics in a research note on Tuesday, July 18th. ValuEngine downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $50.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, July 20th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and sixteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $63.59.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Fox Run Management L.L.C. bought a new position in Sarepta Therapeutics in the 3rd quarter worth about $204,000. Ameritas Investment Partners Inc. increased its stake in Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after acquiring an additional 2,474 shares during the last quarter. Strs Ohio bought a new position in Sarepta Therapeutics in the 3rd quarter worth about $208,000. Finally, Brighton Jones LLC bought a new position in Sarepta Therapeutics in the 3rd quarter worth about $211,000. Institutional investors and hedge funds own 67.76% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.